Skip to content

A Multicenter Randomized Controlled Trial of theTraditional Chinese Formula of Hilling and Clearing Away Heart-fire (HCAH) for Atopic Dermatitis

The Clincal Trial of the Traditional Chinese Formula of Hilling and Clearing Away Heart-fire (HCAH) for Atopic Dermatitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-08000156
Enrollment
Unknown
Registered
2008-07-23
Start date
2009-02-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis

Interventions

Oral administration of Chinese Medicine (group A):The basic prescription is composed of eight herbs, and was modified according to the TCM differentiation of the relative predominance of heart-fire an
Combination therapy of TCM (group B):The oral decoction was the same as for group A.The external wash formula was composed of four dispensing granules, which was used as an external wash for 20 minute
Positive control group (group C):oral administration of antihistamine and a placebo of Chinese medicine pills added to topical 1% mometasone furoate.3% Boric acid solution and zinc oxide ointment were

Sponsors

2nd Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 25 Years

Inclusion criteria

Inclusion criteria: Signed informed consent (or by guardian for those minors); Clinical diagnosis of AD (Hanifin and Rajka criteria); Moderate to Severe flared patients (Rajka and Langeland criteria); Between the age of 5 to 25 years; The course of disease more than 1 year, and the time of anesis less than 3 months.

Exclusion criteria

Exclusion criteria: Unmoral full blood counts and renal and hepatic founction tests; Had any other serious concomitant illness; Other severe skin disease; Who had received systematic corticosteroids, antibiotics, PUVA, or other immunosuppressive treatment within the previous 2 weeks; Pregnancy or intending to become Pregnancy, or were breastfeeding; Epilepsy; Patient included in all other studies; known hypersensitivity to the drug; Abuse of drugs.

Design outcomes

Primary

MeasureTime frame
SCORAD (SCORing Atopic Dermatitis;

Secondary

MeasureTime frame
DLQI (The Dermatology Life Quality Index) or CDLQI;Patients' self-assessment on the severity of disease;

Countries

China

Contacts

Public ContactDacan Chen
4910702@163.com+86 0 13602864954

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 21, 2026